KDMN实时信号 | 通过Getagraph.com最大化利润

Live Chart Being Loaded With Signals

Commentary (1 Jan 1970 @ 08:00):

Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases...

Stats
今日成交量	10.42M
平均成交量	10.03M
市值	0.00
EPS	$-0.200 ( 2021-11-04 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-13.32
ATR14	$0.213 (2.24%)

Insider Trading

Date	Person	Action	Amount	type
2021-11-09	Waksal Harlan	Sell	177 945	Common Stock
2021-11-09	Waksal Harlan	Buy	655 000	Stock Appreciation Right
2021-11-09	Waksal Harlan	Buy	982 500	Performance Stock Option(right to buy)
2021-11-09	Waksal Harlan	Buy	1 350 000	Stock Option (right to buy)
2021-11-09	Waksal Harlan	Buy	2 000 000	Stock Option (right to buy)

INSIDER POWER
0.00
Last 93 transactions
Buy: 16 325 233 \| Sell: 4 159 124

音量相关性

長: 0.23 (neutral)

短: 0.86 (strong)

Signal:(72.9) Same movement expected

Kadmon Holdings Inc 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Kadmon Holdings Inc 相关性 - 货币/商品

0.83
( strong )

-0.16
( neutral )

-0.42
( neutral )

-0.33
( neutral )

0.37
( neutral )

0.55
( weak )

Kadmon Holdings Inc 财务报表

Annual	2020
营收:	$8.29M
毛利润:	$6.29M (75.86 %)
EPS:	$-0.670

FY	2020
营收:	$8.29M
毛利润:	$6.29M (75.86 %)
EPS:	$-0.670

FY	2019
营收:	$5.10M
毛利润:	$3.81M (74.70 %)
EPS:	$-0.480

FY	2018
营收:	$1.40M
毛利润:	$714 000 (51.15 %)
EPS:	$-0.580

Financial Reports:

No articles found.

Kadmon Holdings Inc

Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. Its lead product candidates include KD025, an orally administered selective inhibitor of the rho-associated coiled-coil kinase 2, which is in Phase II clinical trial for the treatment of chronic graft-versus-host and fibrotic diseases; KD045, an oral inhibitor of ROCK for the treatment of fibrotic diseases; and KD033, an anti-PD-L1/IL-15 fusion protein for the treatment of cancer. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease; ribavirin, a nucleoside Inhibitor to treat hepatitis; and CLOVIQUE, a trientine hydrochloride capsules for the treatment of Wilson's disease. Kadmon Holdings, Inc. has strategic collaborations and license agreements with Nano Terra, Inc. and Dyax Corp. The company was founded in 2010 and is headquartered in New York, New York.